AI is transforming drug discovery by boosting early-stage clinical trial success rates to 80%–90%, compared to the traditional 40%–65%, and contributing to nearly half of preclinical drug development output.
Leveraging big data and advanced deep learning models, AI accelerates target identification, molecular design, and clinical trial optimization, saving millions in costs and months in timelines. Notable breakthroughs include AI-designed antibodies and drug repositioning successes.
This article explores how, despite challenges such as data quality and transparency, combining AI with ethical oversight and collaboration promises faster, more precise, and patient-focused pharmaceutical innovation.
By Eratha Poongkuntran, Associate Director, Avasant